Association of estrogen receptor alpha gene polymorphisms with neurofibrillary tangles. 2004

Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
Department of Endocrinology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. hakazama@h4.dion.ne.jp

Estrogen receptor alpha (ERalpha) may be implicated in the pathogenesis of Alzheimer's disease (AD). The aim of this study was to clarify the association between ERalpha gene polymorphisms and AD-related pathologic changes. The staging of neurofibrillary tangles (NFT) and senile plaques (SP) was performed according to the method by Braak and Braak and two polymorphisms, PvuII (P or p) and XbaI (X or x), of the ERalpha gene were typed in 551 Japanese cadavers (294 men and 257 women; mean age, 80.8 years). Distributions of the NFT and SP stages significantly correlated with age (NFT: r = 0.306, p < 0.0001; SP: r = 0.237, p < 0.0001) and were significantly higher in patients with the apolipoprotein E epsilon4 allele (p < 0.0001). Possession of the P allele showed a trend to be associated with a more serious NFT stage, but had no relationship with the SP stage. In men, a significant association between PvuII polymorphism and the NFT stage (p = 0.002) was found, revealing a gene- dose effect of the P allele. Similar results were obtained in the men without the epsilon4 allele (p = 0.011). Multiple regression analyses demonstrated that age was the strongest determinant of the NFT stage, possession of the epsilon4 allele was the next strongest, and PvuII polymorphism was the third strongest (p < 0.0001, R(2) = 0.144). The XbaI polymorphism did affect neither the NFT stage nor the SP stage. In conclusion, the PvuII polymorphism of the ERalpha gene is associated with Braak NFT stages and possession of the P allele may act as a risk factor for AD in Japanese men, especially in those without the epsilon4 allele.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006580 Genetic Carrier Screening Identification of individuals who are heterozygous at a GENETIC LOCUS for a recessive PHENOTYPE. Carriers, Genetic, Detection,Genetic Carriers, Detection,Heterozygote Detection,Carrier Detection, Genetic,Detection, Genetic Carrier,Genetic Carrier Detection,Heterozygote Screening,Carrier Screening, Genetic,Detection, Heterozygote,Screening, Genetic Carrier,Screening, Heterozygote,Screenings, Genetic Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
November 1999, Biochemical and biophysical research communications,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
June 2003, Neuropathology and applied neurobiology,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
June 2012, Genetic testing and molecular biomarkers,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
July 1999, Fertility and sterility,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
February 2016, Scientific reports,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
October 2013, Metabolism: clinical and experimental,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
September 2003, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
September 1987, Journal of the National Medical Association,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
February 2022, Neuropathology and applied neurobiology,
Hirohito Kazama, and Nyoka N Ruberu, and Shigeo Murayama, and Yuko Saito, and Ken-Ichi Nakahara, and Kazutomi Kanemaru, and Hiroshi Nagura, and Tomio Arai, and Motoji Sawabe, and Hiroshi Yamanouchi, and Hajime Orimo, and Takayuki Hosoi
March 2007, Hypertension research : official journal of the Japanese Society of Hypertension,
Copied contents to your clipboard!